Skip to main content
Clinical Trials/NCT05990764
NCT05990764
Recruiting
Not Applicable

Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)

AronPharma Sp. z o. o.1 site in 1 country48 target enrollmentMay 8, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
IBS - Irritable Bowel Syndrome
Sponsor
AronPharma Sp. z o. o.
Enrollment
48
Locations
1
Primary Endpoint
Stool consistency
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of the study is to demonstrate a beneficial effect in reducing symptoms that negatively affect the quality of life of IBS patients, and to demonstrate a positive effect on inflammatory and intestinal function markers.

Detailed Description

The double-blind, randomized, placebo-controlled study will be conducted on 48 patients (18-55 years old) with Irritable Bowel Syndrome (IBS). The study will consist of 2 months of supplementation with three parallel arms: 1) probiotic strains and prebiotic (Partially Hydrolyzed Guar Gum); 2) probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry fruit extract; 3) placebo.The study will assess symptoms associated with IBS, using the IBS-QOL questionnaire and the Bristol Stool Formation Scale. Markers of inflammation and intestinal barrier permeability , will be determined in blood and stool samples collected from patients.

Registry
clinicaltrials.gov
Start Date
May 8, 2023
End Date
January 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed Irritable Bowel Syndrome.
  • Women and men, 18-55 years old.
  • Signed informed consent.

Exclusion Criteria

  • Intake of supplements containing plant extracts, polyphenols or anthocyanins, and supplements containing fiber, probiotics and prebiotics.
  • Participation in another clinical trial.
  • Inability to swallow an oral study drug/placebo.
  • Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant and other gastrointestinal diseases that may affect the results of the study.
  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding,

Outcomes

Primary Outcomes

Stool consistency

Time Frame: Baseline, 2 months

Will be assessed using the Bristol Stool Chart

IBS-QoL (Irritable Bowel Syndrome-Quality of Life) index

Time Frame: Baseline, 2 months

IBS-QoL measures the impact of the disease on the quality of life of patients with IBS

Secondary Outcomes

  • I-FABP(Baseline, 2 months)
  • IL-6(Baseline, 2 months)
  • IL-8(Baseline, 2 months)
  • Zonulin(Baseline, 2 months)
  • Short-chain fatty acids(Baseline, 2 months)

Study Sites (1)

Loading locations...

Similar Trials